WithdrawnPhase 3NCT04006691

Efficacy and Safety of UGN-101 in Recurrent Patients

Studying Medullary thyroid carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
UroGen Pharma Ltd.
Principal Investigator
Ifat Klein, Phd
UroGen Pharma
Intervention
UGN-101 instillations(drug)
Eligibility
18 years · All sexes
Timeline
20192020

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04006691 on ClinicalTrials.gov

Other trials for Medullary thyroid carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Medullary thyroid carcinoma

← Back to all trials